- Home
- GANX vs TURN Comparison
GANX vs TURN Comparison
Compare GANX & TURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- TURN
- Stock Information
- Founded
- GANX 2017
- TURN 1981
- Country
- GANX United States
- TURN United States
- Employees
- GANX N/A
- TURN N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- TURN Finance/Investors Services
- Sector
- GANX Health Care
- TURN Finance
- Exchange
- GANX Nasdaq
- TURN Nasdaq
- Market Cap
- GANX 41.9M
- TURN 35.7M
- IPO Year
- GANX 2021
- TURN N/A
- Fundamental
- Price
- GANX $1.58
- TURN $3.77
- Analyst Decision
- GANX Strong Buy
- TURN
- Analyst Count
- GANX 5
- TURN 0
- Target Price
- GANX $7.60
- TURN N/A
- AVG Volume (30 Days)
- GANX 203.8K
- TURN 37.1K
- Earning Date
- GANX 11-14-2024
- TURN 08-19-2024
- Dividend Yield
- GANX N/A
- TURN N/A
- EPS Growth
- GANX N/A
- TURN N/A
- EPS
- GANX N/A
- TURN N/A
- Revenue
- GANX N/A
- TURN $129,297.00
- Revenue This Year
- GANX N/A
- TURN N/A
- Revenue Next Year
- GANX N/A
- TURN N/A
- P/E Ratio
- GANX N/A
- TURN N/A
- Revenue Growth
- GANX N/A
- TURN 6.32
- 52 Week Low
- GANX $0.89
- TURN $3.12
- 52 Week High
- GANX $5.33
- TURN $4.47
- Technical
- Relative Strength Index (RSI)
- GANX 42.64
- TURN 56.08
- Support Level
- GANX $1.59
- TURN $3.61
- Resistance Level
- GANX $1.70
- TURN $3.75
- Average True Range (ATR)
- GANX 0.15
- TURN 0.11
- MACD
- GANX 0.00
- TURN -0.00
- Stochastic Oscillator
- GANX 19.74
- TURN 45.71
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.